Symbiotec Pharmalab IPO, which was oversubscribed 73.63 times by non-institutional investors, will list on 1 September. The grey market premium is currently +203, indicating a potential listing price above the IPO price of ₹988.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.